Abstract
Stroke induces disorder of gut microbiota; however, whether this disorder differs according to stroke severity and its role in the evolution and outcome of stroke is currently unknown. Here we explored the composition and structure of fecal microbiome based on 68 acute ischemic stroke patients presenting with minor symptoms (admission National Institute of Health Stroke Scale (NIHSS) ≤ 3) and 67 patients with non-minor stroke (admission NIHSS 4-34) using high-throughput Illumina sequencing of the 16S rRNA. There was no significant difference in α-diversity indices, but the principal coordinate analysis of the microbiota indicated clear separation of the two groups. The significantly enriched butyrate-producing genus Roseburia in the minor stroke group was negatively correlated with fasting glucose, while the Erysipelotrichaceae incertae sedis abundant in non-minor stroke patients was positively correlated with stress hyperglycemia (i.e., fasting glucose/glycated hemoglobin ratio). Moreover, the relative abundance of genus Roseburia was also significantly associated with the dynamic changes of NIHSS score, as well as short-term and long-term functional outcomes. Our results suggested that stroke affects microbiota composition in a manner differentiated by stroke severity, and the enrichment of genus Roseburia may play a protective role in stroke evolution and outcome. Our findings strengthen the relevance of specific taxa for stroke severity that might allow targeted therapy in acute ischemic stroke.
Introduction
Acute ischemic stroke (AIS) is a leading cause of global disability, yet clinical outcomes vary significantly among patients. Emerging research into the "gut-brain axis" suggests that stroke triggers intestinal dysbiosis, but it remains unclear if these microbial imbalances differ based on initial stroke severity or if they actively influence long-term recovery. This study investigates whether specific microbial signatures can predict the evolution of neurological deficits and functional outcomes up to one year post-stroke.
Methods
The researchers conducted a prospective observational study of 135 AIS patients at Nanjing First Hospital, China. Patients were categorized into "minor stroke" (NIHSS ≤ 3, n=68) and "non-minor stroke" (NIHSS 4–34, n=67) groups. Fecal samples were collected within 24 hours of admission for 16S rRNA sequencing. To control for confounding variables like age and comorbidities, Propensity Score Matching (PSM) was applied. Statistical analyses included Principal Coordinate Analysis (PCoA) for beta-diversity, Linear Discriminant Analysis Effect Size (LEfSe) for identifying driver taxa, and linear mixed-effects models to correlate microbial abundance with clinical outcomes (NIHSS and modified Rankin Scale).
Results
The study revealed that while overall alpha-diversity—measured by richness and evenness—did not differ significantly between the two groups, the microbial community structure (beta-diversity) showed a clear separation ($p = 0.003$).
A key finding was the enrichment of the genus Roseburia in the minor stroke group. Roseburia is a known producer of butyrate, a short-chain fatty acid (SCFA) that maintains the intestinal barrier and exerts anti-inflammatory effects. Higher Roseburia abundance was associated with a 50% lower risk of poor functional outcome at 30 days (OR 0.50) and a 55% lower risk at one year (OR 0.45).
Conversely, non-minor stroke patients showed a higher Firmicutes to Bacteroidetes (F/B) ratio and enrichment of Erysipelotrichaceae incertae sedis, which positively correlated with stress hyperglycemia (SHG). Since hyperglycemia is a known aggravator of brain tissue damage during a stroke, Roseburia may exert a protective effect by helping regulate glucose metabolism, while other taxa may exacerbate the systemic inflammatory response.
Discussion and Limitations
These findings suggest that the gut microbiome is not merely a reflection of stroke severity but a potential modulator of recovery. The protective role of Roseburia highlights a possible therapeutic target for acute ischemic stroke. However, the study is limited by its single-center design, the lack of a healthy control group, and the use of single-point snapshot sampling at admission. Furthermore, while SCFA production was inferred from taxonomic data, direct metabolomic measurements were not performed. Future research should explore whether interventions like probiotics or fecal microbiota transplants (FMT) can improve outcomes in AIS patients.
Summary updated